Treatment of Parkinson's disease in the advanced stage

Ossig, C.; Reichmann, H.
April 2013
Journal of Neural Transmission;Apr2013, Vol. 120 Issue 4, p523
Academic Journal
Levodopa/Carbidopa, respectively, Levodopa/Benserazide is the most effective treatment for Parkinson's disease and during the progress of the disease, patients will inevitably need to be treated with it. Nonetheless, after a certain time period most of the patients experience side effects. Mainly disturbing are motor and non-motor fluctuations and dyskinesia. Numerous options from changing the medication regimen, to continuos dopaminergic drug delivery via apomorphine or Duodopa pumps and stereotactical interventions are available. The physician's responsibility is to choose the right therapeutic procedure for each timepoint of the patient's disease. In this review, we provide an up to date overview of the available strategies.


Related Articles

  • Continuous Drug Delivery in Parkinson's Disease. Senek, Marina; Nyholm, Dag // CNS Drugs;Jan2014, Vol. 28 Issue 1, p19 

    Development of motor and non-motor complications during the course of Parkinson's disease (PD) is a major challenge for therapeutic management. At advanced disease stages, patients frequently fluctuate between PD symptoms-such as bradykinesia-and dyskinesias, in response to fluctuations in drug...

  • Levodopa.  // Reactions Weekly;9/9/2006, Issue 1118, p13 

    The article presents a case report of a 74-year-old woman and a 65-year-old man who developed permanent mandible dyskinesia with forward and lateral movements after starting treatment with levodopa for Parkinson's disease. During the levodopa challenge, their dyskinesia persisted with no...

  • Preparation of Rotigotine-Loaded Microspheres and Their Combination Use with L-DOPA to Modify Dyskinesias in 6-OHDA-Lesioned Rats. Wang, Aiping; Wang, Lexi; Sun, Kaoxiang; Liu, Wanhui; Sha, Chunjie; Li, Youxin // Pharmaceutical Research;Sep2012, Vol. 29 Issue 9, p2367 

    Purpose: To prepare rotigotine loaded microspheres (RoMS) to achieve continuous dopaminergic stimulation (CDS) for the treatment of Parkinson's disease (PD) and investigate both the therapeutic benefit and inducibility of AIMs of administration of RoMS combination with L-DOPA in 6-OHDA-leisioned...

  • Treatment of Parkinson's Disease. Martin, W.R. Wayne; Wieler, Marguerite // Canadian Journal of Neurological Sciences;Mar2003, Vol. 30, pS27 

    Evaluates pharmacological and nonpharmacological treatments of Parkinson's disease. Administration of levodopa in combination with a peripheral decarboxylase inhibitor to prevent its systematic conversion to dopamine; Effectiveness of the drug; Side effects; Management of drug-induced adverse...

  • Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. Erro, Roberto; Picillo, Marina; Vitale, Carmine; Amboni, Marianna; Moccia, Marcello; Longo, Katia; Cozzolino, Autilia; Giordano, Flavio; De Rosa, Anna; De Michele, Giuseppe; Pellecchia, Maria Teresa; Barone, Paolo // Journal of Neurology, Neurosurgery & Psychiatry;Jan2013, Vol. 84 Issue 1, p14 

    Background: Non-motor symptoms are very common among patients with Parkinson's disease since the earliest stage, but little is known about their progression and their relationship with dopaminergic replacement therapy. Methods: We studied non-motor symptoms before and after 2 years from...

  • The Surgical Management of Parkinson's Disease. Ponce, Francisco A.; Lozano, Andres M. // CNS & Neurological Disorders - Drug Targets;Sep2011, Vol. 10 Issue 6, p685 

    There has been renewed interest in the surgical treatment of Parkinson's disease (PD) over the past 20 years. In the 1940's to 1960's many PD patients underwent neurosurgical procedures to ablate specific brain targets to alleviate tremor and, to a lesser extent, akinesia and rigidity. With the...

  • Targeting Nicotinic Receptors for Parkinson's Disease Therapy. Quik, Maryka; Bordia, Tanuja; Huang, Luping; Perez, Xiomara // CNS & Neurological Disorders - Drug Targets;Sep2011, Vol. 10 Issue 6, p651 

    A promising target for improved therapeutics in Parkinson's disease is the nicotinic acetylcholine receptor (nAChR). nAChRs are widely distributed throughout the brain, including the nigrostriatal system, and exert important modulatory effects on numerous behaviors. Accumulating evidence...

  • Dopamine agonists in early therapy for Parkinson disease: promise and problems. Tanner, Caroline M.; Tanner, C M // JAMA: Journal of the American Medical Association;10/18/2000, Vol. 284 Issue 15, p1971 

    Editorial. Discusses treatment of Parkinson's disease (PD). Benefits and adverse effects of drugs such as levodopa; Reference to a study in this issue by the Parkinson Study Group using pramipexole in the initial therapy; Support for the hypothesis that initial treatment of PD with a...

  • Treatment of Parkinsonism with Levodopa. Lee, John E.; Sweet, Richard D.; McDowell, Fletcher H. // Annals of Internal Medicine;Nov71, Vol. 75 Issue 5, p703 

    Describes the status of patients with Parkinson's disease at the end of 2 years of treatment with levodopa. Common side effects of levodopa; Clinical benefit of levodopa treatment for patients with Parkinson's disease; Recommended dosage of levodopa for the treatment of Parkinsonism.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics